Youcare Pharmaceutical Group Co. Ltd. A
Youcare Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It offers drugs in various forms, such as injection, lyophilized powder for injection, concentrated pills, tablets, capsules, gelatins, ointments, creams, granules, etc. The company provides drugs in various categories, including antibiotics, gastrointest… Read more
Youcare Pharmaceutical Group Co. Ltd. A (688658) - Net Assets
Latest net assets as of September 2025: CN¥3.43 Billion CNY
Based on the latest financial reports, Youcare Pharmaceutical Group Co. Ltd. A (688658) has net assets worth CN¥3.43 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.23 Billion) and total liabilities (CN¥1.80 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.43 Billion |
| % of Total Assets | 65.6% |
| Annual Growth Rate | 25.98% |
| 5-Year Change | -0.03% |
| 10-Year Change | N/A |
| Growth Volatility | 74.64 |
Youcare Pharmaceutical Group Co. Ltd. A - Net Assets Trend (2017–2024)
This chart illustrates how Youcare Pharmaceutical Group Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Youcare Pharmaceutical Group Co. Ltd. A (2017–2024)
The table below shows the annual net assets of Youcare Pharmaceutical Group Co. Ltd. A from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.58 Billion | -0.35% |
| 2023-12-31 | CN¥3.60 Billion | -9.99% |
| 2022-12-31 | CN¥4.00 Billion | +1.78% |
| 2021-12-31 | CN¥3.93 Billion | +9.52% |
| 2020-12-31 | CN¥3.59 Billion | +218.82% |
| 2019-12-31 | CN¥1.12 Billion | +33.46% |
| 2018-12-31 | CN¥842.76 Million | +18.39% |
| 2017-12-31 | CN¥711.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Youcare Pharmaceutical Group Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 89280116020.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥389.55 Million | 10.89% |
| Common Stock | CN¥450.00 Million | 12.58% |
| Other Comprehensive Income | CN¥192.92 Million | 5.39% |
| Other Components | CN¥2.55 Billion | 71.14% |
| Total Equity | CN¥3.58 Billion | 100.00% |
Youcare Pharmaceutical Group Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Youcare Pharmaceutical Group Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NB Bancorp, Inc. Common Stock
NASDAQ:NBBK
|
$667.93 Million |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
$667.97 Million |
|
Taiheiyo Cement Corp
PINK:THYCY
|
$668.21 Million |
|
Toyo Ink SC Holdings Co. Ltd
F:TO5
|
$668.39 Million |
|
Investors Real Estate Trust
F:WXC1
|
$667.49 Million |
|
Guangzhou Wondfo Biotech Co Ltd
SHE:300482
|
$667.47 Million |
|
DINE S.A.B. de C.V
MX:DINEB
|
$667.42 Million |
|
Transcat Inc
NASDAQ:TRNS
|
$667.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Youcare Pharmaceutical Group Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,587,842,712 to 3,577,629,966, a change of -10,212,746 (-0.3%).
- Net income of 123,717,032 contributed positively to equity growth.
- Dividend payments of 111,248,557 reduced retained earnings.
- Share repurchases of 45,033,562 reduced equity.
- Other comprehensive income increased equity by 30,716,703.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥123.72 Million | +3.46% |
| Dividends Paid | CN¥111.25 Million | -3.11% |
| Share Repurchases | CN¥45.03 Million | -1.26% |
| Other Comprehensive Income | CN¥30.72 Million | +0.86% |
| Other Changes | CN¥-8.36 Million | -0.23% |
| Total Change | CN¥- | -0.28% |
Book Value vs Market Value Analysis
This analysis compares Youcare Pharmaceutical Group Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.21x to 2.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.95 | CN¥17.98 | x |
| 2018-12-31 | CN¥2.31 | CN¥17.98 | x |
| 2019-12-31 | CN¥2.49 | CN¥17.98 | x |
| 2020-12-31 | CN¥7.96 | CN¥17.98 | x |
| 2021-12-31 | CN¥8.72 | CN¥17.98 | x |
| 2022-12-31 | CN¥8.86 | CN¥17.98 | x |
| 2023-12-31 | CN¥7.96 | CN¥17.98 | x |
| 2024-12-31 | CN¥8.05 | CN¥17.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Youcare Pharmaceutical Group Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.27%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.60x
- Recent ROE (3.46%) is below the historical average (15.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 22.90% | 5.98% | 0.77x | 4.97x | CN¥91.00 Million |
| 2018 | 32.07% | 6.73% | 1.17x | 4.09x | CN¥184.40 Million |
| 2019 | 25.46% | 6.66% | 1.24x | 3.09x | CN¥173.33 Million |
| 2020 | 12.35% | 10.19% | 0.80x | 1.52x | CN¥84.04 Million |
| 2021 | 13.90% | 10.98% | 0.87x | 1.46x | CN¥152.94 Million |
| 2022 | 8.40% | 7.38% | 0.76x | 1.51x | CN¥-63.71 Million |
| 2023 | 5.15% | 4.40% | 0.71x | 1.65x | CN¥-173.99 Million |
| 2024 | 3.46% | 3.27% | 0.66x | 1.60x | CN¥-234.05 Million |
Industry Comparison
This section compares Youcare Pharmaceutical Group Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Youcare Pharmaceutical Group Co. Ltd. A (688658) | CN¥3.43 Billion | 22.90% | 0.52x | $667.79 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |